Relief Cardiovascular has successfully raised $12 million in a Series A funding round to spearhead its first-in-human feasibility study for the innovative Relief System. This smart transcatheter implant, developed by the Costa Mesa-based company, aims to revolutionize heart failure fluid management by monitoring and regulating renal vein pressures.
The investment will not only launch the feasibility study but also drive further development of the product. With key contributions from Broadview Ventures and Advent Life Sciences leading the financing, other contributors include Pacific Health Investment, Heartwork Capital, and a multinational strategic partner who remains unnamed. Dr. Shahzad Malik from Advent Life Sciences and Dr. Maria Berkman from Broadview Ventures are set to join Relief Cardiovascular’s board, enhancing collaboration and strategy.
Dr. Maria Berkman expressed enthusiasm about the Relief System’s potential impact on heart failure care, citing the device’s role in closing critical gaps in treatment. “With heart failure being such a burden, the Relief System offers a critical solution, and we are thrilled to collaborate with Relief Cardiovascular in bringing this innovative therapy into clinical practice,” Berkman stated.
Echoing this sentiment, Dr. Shahzad Malik highlighted how the system’s dynamic regulation of renal vein pressures addresses challenges faced by patients resistant to diuretics. “By redefining treatment through this innovative approach, the Relief System promises significant advances in patient outcomes,” he noted.
The Relief System features a cutting-edge transcatheter implant that lowers renal vein pressure with a unique ‘puller’ mechanism and autonomously collects vital multiparametric data through integrated sensors. This data-driven design empowers clinicians to offer personalized and effective fluid management solutions.
Dr. William T. Abraham from The Ohio State University noted the potential of this combined monitoring and modulation system: “The Relief System offers a breakthrough in managing heart failure volume dynamics.”
Additionally, according to Dr. Alex Rothman from the University of Sheffield, “Empowered by data-driven interventions, the Relief System facilitates personalized care pathways, proving especially beneficial for patients who don’t respond to traditional diuretics.”